Efficacy and safety of employing an intragastric balloon to manage super obesity, either as a standalone treatment or in combination with GLP-1 receptor agonists.
This study of 67 patients with super obesity demonstrates that combining an intragastric balloon with GLP-1 receptor agonists yields significantly greater weight loss and metabolic improvements compared to balloon monotherapy, while maintaining an acceptable safety profile.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Obesity is a chronic condition that affects the body's ability to manage weight, often leading to serious health issues like heart disease and diabetes. For people with extreme levels of obesity, doctors sometimes turn to surgical solutions, but for those who are too heavy for immediate surgery, there is a less invasive option: an intragastric balloon. This is a soft, silicone device placed inside the stomach through the mouth, which takes up space to make a person feel full sooner and eat less. In recent years, a new class of medications has emerged that helps regulate appetite and blood sugar by mimicking a natural hormone in the body. While both the balloon and these medications have shown promise on their own, researchers have begun to wonder if using them together might work better than either one alone, especially for patients with the highest body mass indices.
A team of researchers at Poznan University of Medical Sciences in Poland set out to test this idea. They focused on 67 patients who were considered to have super obesity, meaning their body mass index was 50 or higher. These patients were preparing for future weight-loss surgery but needed to lose weight first to make the procedure safer. The researchers divided the group into two teams. The first team, consisting of 34 people, received only the intragastric balloon. The second team, with 33 people, received the same balloon but also started taking a medication that mimics the GLP-1 hormone, a type of drug known to help control appetite and blood sugar levels. The goal was to see which group lost more weight, improved their health markers more effectively, and tolerated the treatments without serious side effects.
The results showed a clear difference between the two approaches. Patients who received the combination of the balloon and the medication lost significantly more weight than those who had the balloon alone. After just one month, the group with the combined treatment had lost an average of 10.47 percent of their total body weight, while the balloon-only group lost about 4.61 percent. This gap widened over time. By the six-month mark, the combined group had shed 22.39 percent of their total body weight, compared to only 14.27 percent for the group with the balloon alone. The researchers also measured how much excess weight the patients lost relative to their starting point. After six months, the combined therapy group had lost 61.23 percent of their excess weight, whereas the balloon-only group had lost 41.88 percent.
Beyond the scale, the combination therapy produced better results for the body's internal chemistry. The patients taking the medication alongside the balloon saw greater improvements in their blood sugar levels and cholesterol profiles. Their "bad" cholesterol levels dropped more, and their "good" cholesterol levels rose more compared to the other group. Their blood pressure also decreased more significantly. These metabolic improvements are crucial because obesity often comes with a cluster of health risks, including high blood pressure and diabetes. The study suggests that the medication helps the body maintain the weight loss longer, possibly by stopping the hunger signals that often return once the stomach gets used to the balloon.
Safety was also a major focus of the investigation. The researchers tracked any negative reactions to the treatments. The most common side effects for both groups were nausea and vomiting, which are typical when a balloon is first placed in the stomach. However, the group taking the medication experienced these digestive issues slightly more often, which is consistent with how these drugs work. There were a few rare but serious events in the medication group, including one case of mild pancreatitis and one case of acute gallbladder inflammation, both of which were treated successfully without surgery. There was also one instance of a minor infection at the injection site. Despite these occurrences, the researchers concluded that the safety profile of the combined treatment was acceptable and that the benefits of greater weight loss and better metabolic health outweighed the risks for these patients.
This study provides strong evidence that adding a GLP-1 receptor agonist to intragastric balloon therapy creates a more powerful tool for managing super obesity. While the balloon provides a physical barrier to eating, the medication appears to support the body's natural appetite regulation, helping patients stick to their weight loss goals for longer. The findings suggest that treating severe obesity might require a multi-pronged approach, combining mechanical, pharmacological, and behavioral strategies to achieve the best outcomes. Although the study was conducted at a single center with a relatively small number of patients, the results point toward a future where combining these therapies could become a standard step in preparing patients for definitive weight-loss surgery, offering a safer and more effective path to better health.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.